What the trial was testing
The trial enrolled 16 patients with duchenne muscular dystrophy. The study was sponsored by NS Pharma and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
About 6% of normal dystrophin produced — and timed motor tests improved.
JAMA Neurology · 2020 · NCT02740972
These findings — that dystrophin levels with viltolarsen plus improved timed motor tests in DMD — were published in the JAMA Neurology and represent the headline result of the study.
Researchers tracked outcomes across 16 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with duchenne muscular dystrophy, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Viltolarsen (Viltepso) is FDA-approved and available now for Duchenne muscular dystrophy in patients whose DMD gene mutation can be treated by exon-53 skipping (about 8% of DMD cases). It is a weekly IV infusion. Ask a pediatric neurologist about genetic testing to determine if exon skipping fits.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open duchenne muscular dystrophy trials
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.
CureDuchenne Link®: A Resource for Research
CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and self- and/or caregiver-reported information from participants. Anyone over 4 weeks old who has been diagnosed with DMD or BMD or who is a carrier of DMD or BMD can join. Parents or legal guardians can sign up their child(ren).